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Understanding Melanoma Signaling Networks as the
Basis for Molecular Targeted Therapy
Keiran S.M. Smalley1
Despite years of research, there has been little improvement in survival for patients with disseminated
melanoma. Recent work has identified mutations in BRAF and NRAS, leading to constitutive mitogen-activated
protein kinase (MAPK) pathway as well as constitutive activity in the phosphoinositide 3-kinase (PI3K)/protein
kinase B (AKT) pathway, as being critical events in melanoma growth and progression. In the current review, we
discuss how these complex mutational and signaling profiles can be understood using a network biology
approach, and suggest how an understanding of the key signaling nodes involved in progression and survival
will lead to improvements in melanoma therapy.
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INTRODUCTION
Melanoma is the deadliest form of skin
cancer. It arises from the malignant
transformation of melanocytes, the
pigmented cells of the skin. Incidence
of melanoma continues to increase at
an alarming rate with the National
Institutes of Health predicting 62,480
new cases of melanoma in the year
2008, with 8,420 of these patients
succumbing to their disease. From a
therapeutic standpoint, early detection
of melanoma is vitally important, with
the surgical removal of early stage
(non-metastatic) lesions constituting a
cure. Once disseminated, melanoma
becomes a considerable clinical pro-
blem associated with median survival
times of o6 months. There are cur-
rently no FDA (the Food and Drug
Administration)-approved agents avail-
able that have been shown to alter the
natural history of metastatic disease in
large randomized clinical trials. With
this in mind, a huge amount of research
has been undertaken to increase our
understanding of melanoma biology,
with the hope of discovering new
targets for therapeutic intervention.
High throughput genomic screens have
now identified many of the activating
mutations responsible for melanoma
development/progression, and attempts
are now underway to integrate these
vast data sets (Davies et al., 2002; Lin
et al., 2008). It is becoming clear that
melanoma constitutes a heterogeneous
group of tumors, with different patterns
of oncogenic mutation, overexpression,
and genomic amplification. In this
review, we aim to shed some light on
the complexity and functional redun-
dancy within the melanoma signaling
network, and will discuss how combi-
nation-targeted therapy approaches
may be required to achieve maximal
therapeutic benefit.
Although most studies to date have
focused on the role of individual
signaling pathways, the complexity of
the signaling observed in melanoma
calls for a network biology approach.
The use of network modeling in bio-
logy is a relatively new concept
(Barabasi and Oltvai, 2004). It has been
used most successfully in simple model
organisms, such as yeast, in which
two-hybrid screens have led to the
generation of complete maps of pro-
tein–protein interactions (Jeong et al.,
2001). The interactions between the
various signaling molecules involved in
melanoma progression are best viewed
as a series of links between a number
of interconnected nodes, and the sum
total of all of these nodal links make up
the melanoma cell signaling network.
What these network maps show is that,
although most signaling nodes are
connected by a few links, there are a
few nodes with a great number of links,
which are called hubs. One feature of
these networks is their robustness,
meaning that the removal of one node
from the network will not impair its
function. In melanoma therapy terms,
this means that attacking the network
at one nodal point (for example,
inhibiting MAPK/extracellular signal
regulated kinase (ERK) kinase (MEK))
is unlikely to make the system fail, as
there will be other network connec-
tions that allow the cell to circumvent
the node under attack. Examples from
other biological systems tell us that
attacking the network at the most
connected points, for example, the
network hubs, can lead to system
failure. It is expected that the therapeu-
tic targeting of the critical melanoma
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signaling hubs will lead to apoptosis
and tumor regression.
MUTATIONS THAT ACTIVATE THE
MAPK PATHWAY
Of all the signaling pathways that are
constitutively activated in melanoma,
the most attention has been focused on
the mitogen-activated protein kinase
(MAPK) pathway (Satyamoorthy et al.,
2003; Sharma et al., 2006; Smalley
et al., 2006; Solit et al., 2006). The
MAPK pathway is primarily involved in
the regulation of cell growth. Under
physiological situations, stimulation of
the pathway occurs after the interaction
of growth factors with their respective
cell surface receptors and the transmis-
sion of these signals through the small
GTPase, RAS (Robinson and Cobb,
1997). When active in its GTP-bound
state, RAS activates a number of down-
stream effectors, one of which is the
RAF family of serine/threonine kinases.
There are three isoforms of RAF,
namely, A-Raf, BRAF, and CRAF (also
called Raf-1). Once activated, RAF
stimulates the MAPK cascade, resulting
in the sequential activation of MEK1
and MEK2, which in turn activates
ERK1 and ERK2 (Crews et al., 1992;
Kyriakis et al., 1992). Once activated,
the ERKs either activate cytoplasmic
targets or migrate to the nucleus,
where they phosphorylate transcription
factors.
In melanocytes, the MAPK pathway
is activated by growth factors released
from the local microenvironment, such
as stem cell factor, a-melanocyte-
stimulating hormone, and hepatocyte
growth factor (Mattei et al., 1994). Not
all of these growth factors use the same
mechanism to stimulate the MAPK
pathway. The receptor tyrosine kinases,
such as stem cell factors/c-KIT, stimulate
RAS directly, whereas a-melanocyte-
stimulating hormone—which signals
through G-protein coupled melano-
cortin receptors—requires the prior
activation of adenylate cyclase. Under
physiological conditions, these growth
factors only induce a weak stimulation
of the MAPK pathway that is insuffi-
cient to induce melanocyte prolifera-
tion. In most melanoma cells, the
situation is very different and it has
been shown that 490% of clinical
melanoma specimens have continuous
hyperactivity in the MAPK pathway
(Cohen et al., 2002). Although MAPK
activity in melanoma cells can arise
through autocrine growth factor stimu-
lation (Nesbit et al., 1999), N-cadherin-
based homotypic cell–cell adhesion
(Li et al., 2001), and melanoma cell–-
matrix adhesion, it is more commonly
activated after the acquisition of an
activating oncogenic mutation. The
first such MAPK-activating mutation to
be reported in melanoma was in NRAS
(Padua et al., 1984, 1985). Mutations in
NRAS have since been identified in
15–20% of all melanomas, and are
most commonly the result of the sub-
stitution from leucine to glutamine at
position 61 (Brose et al., 2002; Davies
et al., 2002). A role for RAS mutations
in melanoma initiation has been con-
firmed in animal models, wherein the
introduction of mutated HRAS leads to
melanoma in transgenic mice lacking
expression of the cyclin-dependent
kinase (CDK) inhibitor p16INK4A (Chin
et al., 1997). The most common muta-
tion to be reported in melanoma thus
far is in BRAF, the serine–threonine
kinase located downstream of NRAS
(Davies et al., 2002). Although the
precise mutational frequency varies
according to the study, it seems that
at least 60% of all melanomas harbor
activating mutations in the BRAF gene.
So far, over 50 distinct mutations in
BRAF have been identified (Garnett
and Marais, 2004). Of these, the BRAF
V600E mutation, resulting from a
valine to glutamic acid substitution, is
by far the most common and accounts
for over 80% of all reported BRAF
mutations (Davies et al., 2002; Wan
et al., 2004). Most of the transforming
activity of the BRAF V600E mutation is
thought to result from the stimulation of
the MAPK pathway (Davies et al., 2002).
It is worth noting that not all BRAF
mutations reported are at the V600E
position, and there exist rare sub-
groups of melanomas with D594G
and G469E BRAF mutations (Smalley
et al., 2009). These mutants typically
show low intrinsic BRAF kinase activity
and instead transactivate CRAF to
stimulate their MAPK signaling (Wan
et al., 2004). In common with low-
activity BRAF mutants, melanomas
with activating NRAS mutations are
also known to stimulate MAPK signal-
ing through CRAF rather than BRAF
(Dumaz et al., 2006).
Acquisition of the BRAF V600E
mutation seems to be an early event
in melanoma development with a high
percentage of melanocytic nevi also
found to harbor the mutation (Pollock
et al., 2003). Interestingly, the presence
of the BRAF V600E mutation alone is
not sufficient to oncogenically trans-
form nevi cells into melanoma. Instead,
the forced expression of BRAF V600E
in primary human melanocytes leads
to an irreversible growth arrest charac-
teristic of senescence (Michaloglou
et al., 2005). Pathological studies have
confirmed these in vitro findings, and
showed that most nevi are growth
arrested and express many markers of
senescence (Michaloglou et al., 2005).
This process, termed ‘‘oncogene-
induced senescence,’’ is thought to be
an important mechanism in protecting
cells from malignant change. The
phenomenon has been best character-
ized in fibroblasts and describes a state
in which the acquisition of inappropri-
ate growth signals, such as those from
mutated BRAF, result in the increased
expression of the ARF/p53/p21 axis
as well as the CDK inhibitor, p16
(Sharpless and DePinho, 2005). As the
loss/mutation of the p16 gene is a
common event in some inherited forms
of melanoma (Hayward, 2003), it was
initially thought that the acquisition of
BRAF mutations occurred in tandem
with p16 inactivation. Interestingly, this
seems not to be the case in melanoma
development, with the expression of
p16 in nevi being rather mosaic and
irregular in appearance (Michaloglou
et al., 2005). Follow-up in vitro studies
confirmed these histological findings
and showed that small-interfering RNA
knockdown of p16 in melanocytes did
not lead to malignant transformation
when combined with the BRAF V600E
mutation, nor was the introduction of
BRAF V600E alone found to activate
the ARF/p53/p21 axis (Michaloglou
et al., 2005). Recently, a genome-wide
RNAi (RNA interference) screen has
showed that a secreted protein, insulin
growth factor binding protein-7, in-
duced senescence in melanocytes after
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the introduction of the BRAF V600E
mutation (Wajapeyee et al., 2008).
Mechanistically, the autocrine secre-
tion of insulin growth factor binding
protein-7 acts through a negative feed-
back loop to suppress MAPK signaling
in melanocytes, leading to the induc-
tion of senescence (Wajapeyee et al.,
2008). In contrast, melanoma cells are
able to escape this tumor-suppressive
mechanism by silencing their expres-
sion of insulin growth factor binding
protein-7.
Since the discovery of activating
BRAF and NRAS mutations in melano-
ma, the work of many laboratories
has now unraveled the role of MAPK
signaling in tumor progression. The
best-characterized role for MAPK sig-
naling in melanoma is in the regulation
of cell growth, particularly at the G1
cell cycle checkpoint (Figure 1).
Progression through the G1 restriction
point into the S-phase is driven by
CDK4 and CDK6, which interact with
cyclin D1, as well as by CDK2, which
interacts with cyclins A/E (Sherr, 1994).
Constitutive MAPK activity increases
cyclin D1 and downregulates p27
expression in melanoma cells (Bhatt
et al., 2005). As would be expected,
inhibition of either BRAF or MEK in
melanoma cell lines using pharmaco-
logical inhibitors leads to a profound
G1-phase cell cycle arrest. Indeed,
the BRAF inhibitors, SB590885 (King
et al., 2006), AZ-628 (Montagut et al.,
2008), and PLX-4720, (Tsai et al.,
2008) as well as the MEK inhibitors,
U0126 (Smalley et al., 2007), CI-1040
(Solit et al., 2006), PD0325901, and
AZD6244 (Haass et al., 2008), all have
cytostatic effects on melanoma cells
harboring the BRAF V600E mutation. It
is also suggested that the presence of a
BRAF V600E mutation, rather than an
NRAS or low-activity BRAF mutation,
predicts for sensitivity to both MEK and
BRAF inhibitors (Solit et al., 2006;
Haass et al., 2008; Tsai et al., 2008;
Smalley et al., 2009).
In addition to its role in prolifera-
tion, the MAPK pathway contributes
to a number of other oncogenic
processes. Melanomas are known to
be exceptionally resistant to apoptosis
(Soengas and Lowe, 2003) and it seems
likely that constitutive MAPK activity,
in part, regulates the apoptotic res-
ponse (Figure 2). The induction of
tumor necrosis factor-related apop-
tosis-inducing ligand in melanoma
proceeds through the release of Smac/
DIABLO from the mitochondria (Zhang
et al., 2003), and can be suppressed
by constitutive MAPK. Constitutive
MAPK activity also suppresses apoptosis
through the ribosomal S6 kinase-
mediated inactivation of the pro-apop-
totic protein BAD (Eisenmann et al.,
2003). More recent studies have shown
that the BRAF V600E mutation decrea-
ses the levels of the pro-apoptotic
Bcl-2 family member BIM through an
MAPK-mediated mechanism (Cartlidge
et al., 2008). Constitutive MAPK acti-
vity may also regulate angiogenesis
through the control of hypoxia induci-
ble factor-1a expression (Kumar et al.,
2007). Furthermore, downregulation
of V600E BRAF with small-interfering
RNA significantly decreases the
amount of vascular endothelial growth
factor produced by melanoma cells
(Sharma et al., 2005). This raises the
possibility that melanoma-associated
angiogenesis is partially mediated
by the MAPK pathway. There is also
evidence that BRAF/MAP kinase signal-
ing activity may contribute to the
metastatic spread of melanoma cells
through the regulation of b3-integrin
expression and control of matrix
metalloproteinase expression (Woods
et al., 2001; Benbow et al., 2002; Ge
et al., 2002; Huntington et al., 2004).
Consistent with an anti-metastatic role
for inhibitors of the MAPK pathway,
recent studies have shown that U0126
treatment suppressed lung metastasis
in a mouse melanoma model (Sharma
et al., 2006). There are also possibilities
that BRAF/MAPK signaling may allow
melanoma cells to escape immune
surveillance through suppression of
their highly immunogenic pigmentation
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Figure 1. Sample scheme showing how the BRAF/MEK/ERK and PI3K/AKT signaling pathways
intersect to regulate cell cycle entry and proliferation.
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antigens (Kono et al., 2006). It has been
further shown that treating melanoma
cells with either U0126 or an RNAi to
V600E BRAF mutation reduces the
release of immunosuppressive cyto-
kines from melanoma cells (Sumimoto
et al., 2006) as well as reversing the
suppressive effects of melanoma cell
culture supernatants on dendritic cell
activation.
ACTIVATION OF THE PI3K/AKT
PATHWAY
Activation of the MAPK pathway does
not account for all aspects of mela-
noma progression and there is evidence
that other signaling pathways may be
equally important. The most widely
studied of these is the phosphoinositide
3-kinase (PI3K)/protein kinase B (AKT)
pathway (Stahl et al., 2004; Tsao et al.,
2004). Activation of the PI3K/AKT
pathway in melanoma occurs through
either paracrine/autocrine growth fac-
tors or the loss of expression and/or
mutation of negative pathway regula-
tors. In particular, the insulin-like
growth factor-I is known to aid the
growth of early-stage melanoma cells,
at least in part, through the activation of
PI3K/AKT (Satyamoorthy et al., 2002).
PI3K exists as multiple isoforms, with
type 1a PI3K being the most frequently
activated in cancer (Yuan and Cantley,
2008). Structurally, PI3K forms a het-
erodimer consisting of a p85 regulatory
subunit and a p110 catalytic subunit. It
is recruited to the membrane after the
activation of receptor tyrosine kinases
and associated adaptor proteins that
bind to the SH2 domain of the p85
subunit. The p110 domain can also
be recruited and activated after the
activation of RAS. After membrane
recruitment and activation, PI3K then
phosphorylates the PIP2 (phosphatidyl-
inositol-4,5,bisphosphate) ring at the
30 position, converting PIP2 to PIP3
(phosphatidylinositol-3,4,5,trisphosphate).
Once generated, PIP3 recruits and
activates the downstream serine–
threonine kinases, PDK1 and AKT
(Figure 1). One of the most critical
regulators of AKT is the phosphatase
and tensin homolog (PTEN), which
degrades the products of PI3K, thereby
preventing the activation of AKT. The
mechanism by which the PI3K pathway
is activated in melanoma is not fully
elucidated, but may involve the loss
of expression or functional inactivation
of PTEN. Typically, PTEN expression
is lost in up to 30% of melanoma
cell lines and 10% of human tumor
material. There is also evidence of
inactivating PTEN mutations in 410%
of short-term melanoma cell cultures
(Lin et al., 2008). PTEN can also
function as a haploinsufficient tumor
suppressor, and it is known that allelic
loss of PTEN occurs in at least 58% of
melanoma metastases (Birck et al.,
2000). The AKT family consists of three
members, AKT1–3 (Brazil et al., 2002),
which exhibit different expression
patterns depending on the cell type.
Of these, 43–50% of melanomas have
selective constitutive activity in AKT3
(Stahl et al., 2004). There is evidence
that overexpression of AKT3 may occur
as a result of copy number increases
in the long arm of chromosome 1
(Thompson et al., 1995; Bastian et al.,
1998). Another mechanism for PI3K/
AKT pathway activation in melanoma
is through the acquisition of activating
E17K mutations in AKT3, but this is
thought to be relatively rare (Davies
et al., 2008). AKT has a critical role in
cancer development through its ability
to regulate apoptosis through the direct
phosphorylation of BAD as well as it
effects many other pathways, including
the stimulation of ribosomal S6 kinase,
the inhibition of forkhead signaling,
and the inhibition of glycogen synthase
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Figure 2. Sample scheme showing how the BRAF/MEK/ERK and PI3K/AKT signaling pathways
intersect to regulate apoptosis.
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kinase-3 (Datta et al., 1997; Robertson,
2005) (Figure 2).
The PI3K/AKT signaling has a role in
melanoma initiation, with recent stu-
dies showing that AKT transforms
melanocytes under hypoxic conditions
through a mechanism involving Notch
signaling (Bedogni et al., 2005, 2008).
Another study has shown a requirement
for constitutive AKT activity in the
BRAF V600E mutation-mediated devel-
opment of melanoma (Cheung et al.,
2008). Consistent with the role of PI3K/
AKT signaling in melanoma progres-
sion, inhibition of the pathway, using
either PI3K inhibitors or RNAi’s against
AKT3, reduces melanoma growth and
induces apoptosis (Stahl et al., 2004).
Although small molecule inhibitors of
both PI3K and AKT are now available,
the clinical development of PI3K inhi-
bitors is more advanced, with three
inhibitors (BEZ-235, BGT-226, and
PX-866) currently undergoing phase I
evaluation. A recent pre-clinical
study on PX-866, which is a modified
analog of wortmannin, showed signifi-
cant inhibition of growth and inva-
sion under three-dimension melanoma
spheroid culture conditions (Howes
et al., 2007). The PI3K/AKT pathway
is known to regulate proliferation of
melanoma cells, through the regulation
of cell cycle entry at the G1 checkpoint
(Smalley et al., 2007) and through the
inactivation of GSK-3b, leading to
cyclin D1 degradation (Diehl et al.,
1998) (Figure 1).
Another signaling cascade inti-
mately linked to the PI3K/AKT pathway
is the mammalian target of rapamycin
(mTOR) pathway. mTOR signaling
involves the activity of two signaling
complexes, mTORC1 and mTORC2.
Structurally, the mTORC1 complex
consists of mTOR as well as the
regulatory proteins, raptor and mLST8.
Activation of the mTORC1 signaling
complex leads to the phosphorylation
and activation of p70 S6 kinase and
to the eukaryotic initiation factor, 4E-
binding protein (Reiling and Sabatini,
2006). Increased activity in these two
downstream pathway components
leads to increased protein translation
and cell proliferation (Figure 1). In
contrast, the mTORC2 complex also
consists of mTOR and mLST8, as well
as the regulatory proteins, rictor and
mSin-1. The two different mTORC
complexes have opposite effects on
AKT signaling, with mTORC1 suppres-
sing AKT signaling and mTORC2
directly activating AKT through a phos-
phorylation event at Ser473 (Sarbassov
et al., 2004). There is also evidence
that mTORC1 inhibition may lead to
increased PI3K/AKT signaling through
the upregulated expression of the
insulin-like growth factor-I adaptor
protein IRS2 (Tamburini et al., 2008).
Thus, there has been some concern that
the clinical use of mTORC1 inhibitors
may lead to a rebound increase in AKT
signaling. mTOR signaling is known to
be active in melanoma, with immuno-
histochemical studies showing the
constitutive phosphorylation of p70 S6
kinase in a panel of metastatic mela-
noma samples (Karbowniczek et al.,
2008). Further work has shown that
rapamycin has growth inhibitory acti-
vity across a small panel of human
melanoma cell lines, and that this may
synergize with either sorafenib or
bevacizumab (Molhoek et al., 2005,
2008). Although initial clinical trials of
rapamycin analogs in melanoma were
essentially negative (Margolin et al.,
2005), there are preliminary indica-
tions that rapamycin may have activity
in melanoma patients in combination
with carboplatin and paclitaxel (Meier
et al., 2009).
BOTH PI3K/AKT AND BRAF/AKT
SIGNALING ARE REQUIRED FOR
MELANOMA PROGRESSION
It is clear from pre-clinical studies that
the BRAF/MAPK and the PI3K/AKT
pathways have overlapping functions
with regard to melanoma progression
(Figures 1 and 2). Analysis of melano-
ma lines and human melanoma sam-
ples have shown that mutational
profiles are favored that simultaneously
promote both MAPK and PI3K/AKT
signaling (Tsao et al., 2000, 2004). As
activating NRAS mutations can stimu-
late both the MAPK and PI3K/AKT
pathways, they are rarely found in
concert with BRAF mutations and these
mutations are mutually exclusive. Like-
wise, BRAF mutations are frequently
found in combination with either PTEN
loss/inactivation or activating AKT3
mutations, again showing a require-
ment for dual MAPK and PI3K/AKT
pathway activity (Tsao et al., 2004;
Davies et al., 2008; Lin et al., 2008).
AKT3 seems to cooperate with the
BRAF V600E mutation in melanoma
initiation by suppressing MAPK signal-
ing activity through phosphorylation at
Ser364/428 of BRAF (Cheung et al.,
2008). It is therefore suggested that
AKT3’s ability to downregulate MAPK
activity may allow early-stage melano-
ma cells to escape from oncogene-
induced senescence. The strongest
proof of concept for the cooperation
between the BRAF V600E mutation and
PI3K signaling in melanoma develop-
ment is derived from the mouse mod-
eling work of Martin McMahon and
Marcus Bosenberg (Dankort et al.,
2009). These authors have elegantly
shown that the conditional expression
of melanocyte-specific mutated BRAF
alone led to the development of
benign melanocytic hyperplasia but
not melanoma. Full transformation to
melanoma occurred only when the
BRAF-V600E mutation was activated
in the presence of PI3K/AKT activity
after suppression of PTEN expression
(Dankort et al., 2009).
The melanoma network is highly
interconnected with a great deal of
functional redundancy built into it
(sample network shown in Figure 3).
This is particularly true with regard to
the fact that inhibition of either PI3K or
MEK alone can inhibit melanoma
growth and both the PI3K/AKT and
MEK signaling pathways regulate apop-
tosis at some level (Stahl et al., 2004;
Smalley et al., 2006, 2007; Solit et al.,
2006; Tran et al., 2008). Studies have
already shown that single-agent MEK
inhibition is relatively ineffective at
inducing melanoma regression in both
pre-clinical models (Haass et al.,
2008) and in early-phase clinical trials
(Rinehart et al., 2004; Lorusso et al.,
2005; Adjei et al., 2008). The disap-
pointing clinical activity seen after
single-agent MEK inhibition parallels
with that observed with single-agent
sorafenib (Eisen et al., 2006). However,
there is some suggestion of benefit
when sorafenib is combined with
either carboplatin/paclitaxel or dacar-
bazine (McDermott et al., 2008). The
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mechanism by which BRAF/MEK inhi-
bition enhances response to chemo-
therapy in melanoma is currently under
investigation (Smalley and Flaherty,
2009).
The signaling pathways active in
melanoma cells are interconnected
through multiple feedback loops; there-
fore, inhibition of one pathway often
leads to the activation of a parallel
pathway (Figure 3). This is best char-
acterized in the case of mTOR inhibi-
tion, which leads to a rebound increase
in MAPK signaling through a PI3K-
mediated mechanism (Carracedo et al.,
2008). These kinds of reciprocal
relationships between the signaling
pathways active in melanoma argue
strongly in favor of combined targeted
therapy strategies. Recent work from
our laboratory has identified other sites
of redundancy within the melanoma
signaling network, with cyclin D1
amplifications being found in concert
with BRAF V600E mutations in minor
sub-groups of melanomas (Smalley
et al., 2008b). Others have shown that
the melanocyte survival factor, MITF
(microphthalmia-associated transcrip-
tion factor), is also amplified in a small
sub-group of BRAF V600E-mutated
melanomas, and that this in turn
regulates CDK2 and Bcl-2 expression
(McGill et al., 2002; Du et al., 2004;
Garraway et al., 2005).
The melanoma signaling network is
also highly robust, with BRAF-V600E-
mutated melanoma cells rapidly deve-
loping resistance to BRAF inhibition
in vitro (Montagut et al., 2008). Rather
than this resulting from an acquired
genetic change in the melanoma cells,
resistance instead results from a simple
switching within the MAPK pathways
so that the signal is routed from
BRAF to CRAF (Figure 3). Studies on
melanoma cell lines harboring NRAS
mutations have already shown that
melanomas can use CRAF as a mecha-
nism to activate downstream MAPK
signaling (Dumaz et al., 2006). The
presence of a network connection that
can easily switch MAPK signaling
from BRAF to CRAF is suggestive of
a mechanism by which resistance to
BRAF inhibitors may be acquired.
There is also redundancy at the level
of melanoma survival, with BRAF/MEK
inhibition being associated with the
induction of a G1-phase cell cycle
arrest but little apoptosis (Verhaegen
et al., 2006). This is a surprising finding
given that BRAF signaling directly
regulates the expression of the pro-
apoptotic protein, BIM, in melanoma
cells, and that the inhibition of MEK
or BRAF can lead to an increase in
its expression (Cartlidge et al., 2008)
(Figure 2). In this instance, it seems that
the high level of Bcl-2 expression
that is often observed in melanoma
counteracts the pro-apoptotic activity
of BIM (Cragg et al., 2008). This
redundancy can be easily overcome
when combination therapy approaches
are used. Recent work has shown
that the combined administration of
a MEK inhibitor with a BH3 family
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Figure 3. Sample melanoma signaling networks. (a) A simplified view of the melanoma signaling network. Nodes shown in green indicate points where there
are either activating oncogenic mutations or increases in protein expression. Some of the nodes are highly interconnected, such as AKT and BAD, and may
represent hubs within the network. It is likely that the real melanoma signaling network is far more interconnected and complex than the scheme indicated
above. Points of network attack are shown in (b) Imatinib treatment or in (c) BRAF inhibitor treatment.
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(Bcl-2 family) mimetic, ABT-737, leads
to massive apoptosis induction (Cragg
et al., 2008).
The challenge for melanoma thera-
pists is to identify the key signaling
hubs in the melanoma network to
ensure that the cell proliferation/
survival network fails. There are clearly
examples in cancer biology, in which
the identification and pharmacological
targeting of the correct network hub
can lead to network failure (for exam-
ple, apoptosis) and impressive clinical
results. These approaches have been
best characterized for tumors, in which
survival and progression are driven by a
single oncogenic event that regulates
the entire signaling network, for
example Bcr-Abl in chronic myeloid
leukemia (Druker et al., 2001). Similar
observations have been made for the
minor sub-group of acral lentiginous/
mucosal melanomas that harbor acti-
vating c-KITmutations. In these tumors,
c-KIT signaling does seem to be the
critical network hub, and a limited
number of patients with c-KIT-mutated
melanomas have shown impressive
responses to the c-KIT inhibitor, im-
atinib mesylate (Gleevec, Novartis, East
Hanover, NJ) (Curtin et al., 2006; Hodi
et al., 2008; Lutzky et al., 2008). There
are also reports of a mucosal melano-
ma patient harboring a V560D muta-
tion in c-KIT showing a complete
response to sorafenib (Quintas-Carda-
ma et al., 2008). It is currently unclear
whether the presence of high levels of
c-KIT receptor protein or an activating
mutation predicts for effective response
to imatinib. A recent phase II clinical
trial of 21 melanoma patients reported
one clinical response in a patient with
acral lentiginous melanoma exhibiting
high c-KIT receptor expression but no
evidence of c-KIT mutation (Kim et al.,
2008).
From a mechanistic standpoint, it
seems that c-KIT-dependent melano-
mas still require MEK signaling; how-
ever, MEK inhibition is only cytostatic
in these cell lines, in which inhibition
of c-KIT signaling leads to apoptosis
(Smalley et al., 2008a). Further studies
have shown that treating c-KIT-depen-
dent melanomas with imatinib leads to
the simultaneous inhibition of MAPK,
PI3K/AKT, and JAK/STAT signaling
pathway activity, which likely accounts
for the apoptosis observed (Jiang et al.,
2008) (Figures 2 and 3).
The findings from studies on c-KIT-
dependent melanomas suggest that
multiple signaling pathways need to
be inhibited simultaneously. Most
studies to date have focused on either
the combination of MEK and PI3K
signaling or on BRAF/MEK and mTOR
signaling. Under three-dimension cell
culture and xenograft conditions, in
which drug resistance is increased,
single-agent treatment with either an
MEK or PI3K inhibitor is ineffective
at blocking growth, whereas the dual
combination is highly effective
(Bedogni et al., 2004; Smalley et al.,
2006). Likewise, the liposomal admin-
istration of an RNAi against BRAF is
relatively weak at suppressing the
growth of melanoma xenografts alone,
but markedly potentiated when com-
bined with an small-interfering RNA
against AKT3 (Tran et al., 2008).
There is evidence of synergistic pro-
apoptotic activity between sorafenib/
MEK inhibitors and rapamycin in
pre-clinical models of melanoma
(Molhoek et al., 2005; Meier et al.,
2007; Lasithiotakis et al., 2008). From a
mechanistic standpoint, the combina-
tion of MEK/mTOR inhibition reduces
the expression of Mcl-1 and Bcl-2
leading to enhanced levels of apoptosis
(Lasithiotakis et al., 2008).
As melanomas also exhibit constitu-
tive activity in multiple other pathways,
including nuclear factor kappa B, Src,
JAK/STAT3, Wnt, hedgehog, and Notch
(Yang and Richmond, 2001; Niu et al.,
2002; Balint et al., 2005; Stecca et al.,
2007), the identification of combina-
tion therapies for melanoma will re-
quire a systematic screening approach,
in which pairwise combinations of
signal transduction inhibitors are
tested, in turn, across panels of mela-
noma cell lines with defined patterns of
genetic mutation. This synthetic lethal
approach will identify the critical pairs
of signaling hubs that need to be
targeted in melanoma for maximal
therapeutic effect. An increased under-
standing of the temporal regulation of
melanoma signaling can also be used
to therapeutic advantage. Tumors
that show ‘‘oncogene addiction’’ have
constitutive activity in many signaling
pathways, some anti-apoptotic activity
and others pro-apoptotic (Sharma and
Settleman, 2006). When the activity of
the driving oncogene is disrupted using
a pharmacological inhibitor, the cells
typically undergo apoptosis. There
seems to be a temporal component to
this apoptosis induction in that the
pro-survival signaling activity, such as
AKT and MAPK, tends to decrease
quickly after targeted therapy treat-
ment, whereas the pro-apoptotic sig-
nals driven through the stress-activated
protein kinases, p38 and JNK, tend
to persist for many hours after drug
treatment (Johnson et al., 2000; Parmar
et al., 2004). The combined inhibition
of BRAF/MEK and PI3K/AKT signals
could be highly effective in melanoma,
in part, by allowing the pro-apoptotic
signals present to dominate.
We stand today at the crossroads
of melanoma therapy. A greater knowl-
edge about the complexity and
redundancy that lies within the multi-
ple pathways responsible for melano-
ma progression is opening up exciting
new avenues for investigation. Already
a whole array of molecular targeted
agents against BRAF signaling
(PLX-4032, RAF-265), MEK signaling
(AZD6244, PD0325901), AKT
(GSK690693), and mTOR (CCI-779,
RAD-001) are undergoing clinical
evaluation. It is hoped that continued
investigation will lead to the long
needed breakthrough in the treatment
of melanoma.
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